Summary & Overview

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes without MCC: Inpatient Reimbursement Overview

DRG 641 encompasses miscellaneous disorders of nutrition, metabolism, fluids and electrolytes without Major Complication or Comorbidity, including conditions such as mild electrolyte disturbances and nutritional deficiencies that do not meet higher-severity criteria. Understanding this Diagnosis-Related Group matters for inpatient reimbursement because it determines grouping and relative payment weight under Medicare's prospective payment system.

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes without MCCDRG Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes without MCCDRG 641Diagnosis-Related GroupInpatient ReimbursementMedicareInternal MedicineClinical NutritionNephrologyHospital Coding

DRG 641 Overview

DRG 641 covers hospital stays for miscellaneous disorders of nutrition, metabolism, fluids and electrolytes without Major Complication or Comorbidity. Typical cases include electrolyte imbalances, malnutrition assessments, and metabolic disturbances that do not carry a Major Complication or Comorbidity. This Diagnosis-Related Group is relevant to inpatient payment because it groups clinically related cases with similar resource use for Medicare reimbursement. Accurate coding within this group influences assignment of payment weight and hospital revenue.

National Payment Rates

Across commercial payers the observed payment rates range roughly from $370 up to $27K, with commercial medians clustered around $12K–$14K in several plans. The widest spread is between BCBS (min ~$370, max $20K) and Anthem (min ~$390, max $27K), reflecting a payer-to-payer range of about $27K. See the table and chart below for payer-level detail.

Mean Rates by Payer — National — DRG 641

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($7.4k), average submitted covered charges ($34.7k), average Medicare payment ($5.6k), and total discharges (65.3k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s mean reimbursement for DRG 641 ranges from $12K to $19K across payers, with Cigna at the high end and Blue Cross Blue Shield and Anthem at the low end. The state exhibits a relatively narrow payer spread but Cigna’s mean sits noticeably above the other state payers. This represents a meaningful deviation from national averages where means are generally lower or more varied for some payers. See the table and chart below for detailed payer-level benchmarks.

Key Insights for Alaska

Highest payer: Cigna at a mean of $19K; Lowest payers: Blue Cross Blue Shield and Anthem at a mean of $12K.
Alaska’s mean rates range from $12K to $19K, with Cigna notably above the other state payers and modestly higher than national means for some payers.

Clinical Trials

Acute electrolyte and fluid management trials: randomized or pragmatic studies evaluating rapid correction strategies for common inpatient electrolyte disturbances (such as severe hyponatremia, hyperkalemia, or symptomatic hypocalcemia) and protocols for intravenous fluid selection and dosing in hospitalized adults. These studies enroll patients admitted for acute metabolic derangements or dehydration who require urgent inpatient correction, and they compare safety endpoints such as rates of overcorrection, arrhythmia, and need for ICU transfer as well as short-term clinical recovery. Results inform inpatient clinical pathways and utilization of monitoring resources, which directly affect length of stay and cost drivers important to providers and payers for this DRG.
Comparative effectiveness and care-delivery studies for nutrition and glycemic management: prospective cohort studies or randomized comparative trials examining enteral versus parenteral nutrition strategies, timing of nutritional initiation, or differing inpatient glycemic control protocols in medically complex patients with malnutrition, prolonged NPO status, or steroid-induced hyperglycemia. These trials typically target general medicine inpatients with malnutrition risk or metabolic comorbidities and assess outcomes such as infection rates, wound healing, readmission, and total inpatient resource use. Findings help determine best practices that reduce complications and readmissions, thereby guiding reimbursement policies and care pathways for this heterogeneous group.
Post-discharge outcomes and transitional care research: observational and interventional studies focused on reducing readmissions and adverse events after discharge for patients treated for fluid, electrolyte, or metabolic disorders—examples include discharge monitoring programs, remote electrolyte surveillance, or pharmacist-led medication reconciliation for diuretics and potassium supplements. These studies follow patients after hospital discharge to measure readmission rates, ED visits, and outpatient resource utilization, often enrolling older adults or those with multiple comorbidities common in this DRG. Evidence from these studies supports care coordination interventions and payment models aimed at lowering post-discharge costs and improving quality metrics that affect provider reimbursement.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$7.4K	$35K	$5.6K	65K

Acute electrolyte and fluid management trials: randomized or pragmatic studies evaluating rapid correction strategies for common inpatient electrolyte disturbances (such as severe hyponatremia, hyperkalemia, or symptomatic hypocalcemia) and protocols for intravenous fluid selection and dosing in hospitalized adults. These studies enroll patients admitted for acute metabolic derangements or dehydration who require urgent inpatient correction, and they compare safety endpoints such as rates of overcorrection, arrhythmia, and need for ICU transfer as well as short-term clinical recovery. Results inform inpatient clinical pathways and utilization of monitoring resources, which directly affect length of stay and cost drivers important to providers and payers for this DRG.
Comparative effectiveness and care-delivery studies for nutrition and glycemic management: prospective cohort studies or randomized comparative trials examining enteral versus parenteral nutrition strategies, timing of nutritional initiation, or differing inpatient glycemic control protocols in medically complex patients with malnutrition, prolonged NPO status, or steroid-induced hyperglycemia. These trials typically target general medicine inpatients with malnutrition risk or metabolic comorbidities and assess outcomes such as infection rates, wound healing, readmission, and total inpatient resource use. Findings help determine best practices that reduce complications and readmissions, thereby guiding reimbursement policies and care pathways for this heterogeneous group.
Post-discharge outcomes and transitional care research: observational and interventional studies focused on reducing readmissions and adverse events after discharge for patients treated for fluid, electrolyte, or metabolic disorders—examples include discharge monitoring programs, remote electrolyte surveillance, or pharmacist-led medication reconciliation for diuretics and potassium supplements. These studies follow patients after hospital discharge to measure readmission rates, ED visits, and outpatient resource utilization, often enrolling older adults or those with multiple comorbidities common in this DRG. Evidence from these studies supports care coordination interventions and payment models aimed at lowering post-discharge costs and improving quality metrics that affect provider reimbursement.

OpenPayer

Summary & Overview

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes without MCC: Inpatient Reimbursement Overview

DRG 641 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes